Corbus Pharmaceuticals insider Ben Yong sold 2,000 shares at $7.84 each on September 14, 2026. The transaction left him with 9,383 shares and represented about 17.6% of his prior holding, giving investors a clear measure of the change in his personal position.
Key Highlights
- Ben Yong held 9,383 Corbus Pharmaceuticals shares after the transaction.
- The sale represented about 17.6% of Yong’s prior shareholding.
- Ben Yong sold 2,000 Corbus Pharmaceuticals Holdings, Inc. shares at $7.84 per share on September 14, 2026.
- The transaction was reported in a Form 4 filed with the SEC under transaction code S.
Transaction Details
Ben Yong, an insider of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), sold 2,000 shares on September 14, 2026. The shares were sold at $7.84 per share, according to a Form 4 filed with the SEC.
Post-Transaction Holdings
Following the transaction, Yong owned 9,383 shares of Corbus Pharmaceuticals Holdings, Inc. The filing states that the 2,000 shares sold represented about 17.6% of Yong’s prior shareholding in the company. The transaction was identified with SEC transaction code S. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Corbus Pharmaceuticals shares did Ben Yong sell?
A: Ben Yong sold 2,000 Corbus Pharmaceuticals shares at $7.84 per share on September 14, 2026. The transaction used code S.
Q: How many CRBP shares did Ben Yong own after the sale?
A: Ben Yong owned 9,383 Corbus Pharmaceuticals shares after the transaction. The remaining holding reflects his position following the insider sale.
Q: What percentage of Ben Yong’s prior holding did the sale represent?
A: The Corbus Pharmaceuticals insider transaction represented about 17.6% of Ben Yong’s prior shareholding. Transaction code S identifies it as an open-market sale.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.